Title: *Observational assessments of the relationship of dietary and pharmacological treatment on continuous measures of dysglycemia over 24 hours in women with gestational diabetes*

Cassy F. Dingena[1], Melvin J. Holmes[1], Matthew D. Campbell[2], Janet E. Cade[1], Eleanor M. Scott[3], Michael A. Zulyniak[1]

[1]School of Food Science and Nutrition, University of Leeds, Leeds, U.K.
[2] School of Nursing and Health Sciences, Institute of Health Sciences and Wellbeing, University of Sunderland, Sunderland, U.K.
[3]Department of Clinical and Population Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.

Sponsor: The supporting source had no involvement in study design; collection, analysis, and interpretation of data; writing of the report; or imposed any restrictions regarding the submission or publication of the report.

Conflict of Interest and Funding Disclosure: No conflicts of interest. C.F.D. is currently funded by The University of Leeds Studentship and M.A.Z. is currently funded by the Wellcome Trust (217446/Z/19/Z).

Clinical trial registration:

Corresponding Author: Michael Zulyniak, School of Food Science and Nutrition, University of Leeds, Leeds, U.K. Email. m.a.zulyniak@leeds.ac.uk

Running title: Effect of treatment on CGM in women with GDM

Abbreviations:

AUC	Area under the curve
BMI	Body Mass Index
CGM	Continuous glucose monitoring
CV	Coefficient of variation
GDM	Gestational diabetes mellitus
GI	Glycemic index
iAUC	Incremental area under the curve
NICE	National Institute for Health and Care Excellence
OR	Odds ratio
PPG	Postprandial glucose
PPGR	Postprandial glucose response
RDI	Recommended daily intakes
SD	Standard deviation
SMBG	Self-monitored blood glucose
T2DM	Type 2 diabetes mellitus
TAR	Time above range
TBR	Time below range
TIR	Time in range

Abstract

Objectives – Studies that use continuous glucose monitoring (CGM) to monitor women with gestational diabetes (GDM) highlight the importance of managing dysglycemia over a 24-hour period. However, the effect of current treatment methods on dysglycemia over 24-hrs are currently unknown. This study aimed to characterise CGM metrics over 24-hrs in women with GDM and the moderating effect of treatment strategy.

Methods – Retrospective analysis of CGM data from 128 women with GDM in antenatal diabetes clinics. CGM was measured for 7-days between 30-32 weeks gestation. Non-parametric tests were used to evaluate differences of CGM between periods of day (morning, afternoon, evening, and overnight) and between treatment methods (i.e., diet alone or diet+metformin). Exploratory analysis in a subgroup of 34 of participants was performed to investigate the association between self-reported macronutrient intake and glycaemic control.

Results – Glucose levels significantly differed during the day (i.e., morning to evening; $P<0.001$) and were significantly higher (i.e., mean blood glucose and AUC) and more variable (i.e., SD and CV) than overnight glucose levels. Morning showed the highest amount of variability (CV; 8.4% vs 6.5%, $P<0.001$ and SD; 0.49 mmol/L vs 0.38 mmol/L, $P<0.001$). When comparing treatment methods, mean glucose (6.09 vs 5.65 mmol/L; $P<0.001$) and AUC (8760.8 vs 8115.1 mmol/L.hr; $P<0.001$) were significantly higher in diet+metformin compared to diet alone. Finally, the exploratory analysis revealed a favourable association between higher protein intake (+1SD or +92 kcal/day) and lower mean glucose (-0.91 mmol/L p, $P=0.02$) and total AUC (1209.6 mmol/L.h, $P=0.021$).

Conclusions – Glycemia varies considerably across a day, with morning glycemia demonstrating greatest variability. Additionally, our work confirms that individuals assigned to diet+metformin have greater difficulty managing glycemia and results suggest that increased dietary protein may assist with management of dysglycemia. Future work is needed to investigate the benefit of increased protein intake on management of dysglycemia.

Keywords: GDM; Continuous Glucose Monitoring; Glycemia; Diet; Metformin; Protein; myfood24

Introduction

Pregnancy induces a natural state of insulin resistance (IR) to shuttle a greater proportion of maternal nutrients to the infant for growth and development (1). However, in 5-18% of all UK pregnancies (2, 3) this metabolic shift leads to uncontrolled and unhealthy increases in blood glucose (1, 4-6), known as gestational diabetes mellitus (GDM). GDM occurs when women not previously known to have diabetes develop hyperglycemia during pregnancy, risking the health of mother and growing offspring (5, 7). Moreover, GDM is associated with increased risk of pre-eclampsia, preterm delivery, and type 2 diabetes (T2DM) in later life (8); while offspring exposed to GDM in utero are at increased risk of abnormal birth weight, birth injury, mortality, and obesity and T2DM in later life (7-9). Treatment aims to control maternal glucose levels and mitigate adverse pregnancy outcomes and long-term maternal and offspring health risks (10).

The first line of treatment for GDM typically consists of dietary and lifestyle education (1, 11). Diets focussing on low glycaemic index (GI) foods and reduced overall carbohydrate intake are most common for the management of GDM(1, 3) but no consensus on the best nutritional approach has been agreed (12, 13). In the UK, clinical recommendations focus on improving carbohydrate quality and reducing overall carbohydrate intake (3, 6). While replacing simple carbohydrates with higher-quality carbohydrates and lower overall carbohydrate intake can help to control glucose levels, its effectiveness on managing dysglycemia is not consistent between populations (13), with meta-analyses demonstrating high levels of heterogeneity (>60%) of low GI diets on fasting and post-prandial glucose levels (14). This may be because trials often prescribe specific low-GI nutrients to be consumed at defined times over a 24-hour period, while real-life meals are often mixtures of foods consumed at various points throughout the day (15-17). Previous research has demonstrated that dietary protein can attenuate the subsequent rise in the postprandial glucose response (PPGR) (18, 19). However, free living individuals consume meals that consist of mixed macronutrients consumed at different times of the day, suggesting that a single measure of post-prandial glucose (PPG) may be inadequate to characterise the full effect of diet on dysglycemia.

Randomised controlled trials suggest that 80% of women with GDM can achieve normal glucose levels through diet and lifestyle modification alone (20). However, where management of dysglycemia is more difficult, pharmacological therapy may be needed. Metformin, an oral

antihyperglycemic drug, has been used as a secondary line treatment for glycemic control in

T2DM for decades (21, 22). In women with GDM, the UK clinical guidelines also recommend

metformin as secondary-line treatment in the management of dysglycemia (3), with added

benefits linked to reduced gestational weight gain, maternal hypertensive disorders, macrosomia,

neonatal hypoglycemia, and intensive care unit admissions (3). Current evidence suggests no

difference in standard maternal measures of glycaemia or neonatal outcomes after delivery in

women treated with either diet or metformin (23).

However, maternal glucose is dynamic, glucose tolerance and insulin sensitivity vary over a 24-

hour period (24, 25), and emerging evidence suggests that glycaemic spikes and patterns rather

than single measures of glycaemia may be more indicative of poor dysglycemic management and

provide novel information regarding maternal and offspring health risks (26). These details are

captured using continuous glucose monitors (CGM), which repeatedly record glucose measures

in close succession (minutes) over a specific period of time (days or weeks), and offer detailed

records of glucose dynamics (27). The capabilities of CGM recently demonstrated novel

associations between CGM-defined markers of dysglycemia at (i) 12-weeks' gestation with infant

health outcomes [i.e., preterm birth: OR = 1.52 (1.08, 2.13); large-for-gestational age: OR = 1.49

(1.06, 2.08)] and (ii) 24 -week gestation with maternal outcomes [pre-eclampsia: OR = 1.98

(1.17, 3.37)] (28). This suggests that CGM can (i) offer new information regarding the

association between dysglycemia, and maternal and offspring health, and (ii) be used to inform

and direct care more accurately and at an earlier point of pregnancy. Interestingly, CGM has not

yet been used to evaluate the relationship between lifestyle treatment with or without metformin

to glucose spikes and variability over a 24-hour period in women with GDM, which could offer

novel insights regarding treatment strategies (i.e., diet or diet+metformin) as mediators of

dysglycemia across the day in GDM pregnancies. Therefore, this study aimed to determine key

time points during the day of disrupted glucose control, and the relationship of treatment and

dietary mediators to this disrupted glucose control in a diverse population of pregnant women

with GDM.

Methods

Study Design

Secondary retrospective analysis of an observational cohort of 162 pregnant women with GDM

(2). Of 162 women, 128 had complete participant data and < 30% missing CGM data across the 7

days. CGM data was collected between 16/01/2014 and 23/08/2016. All women provided written

informed consent. The study was approved by the Yorkshire and Humber Regional Ethics

Committee (13/YH/0268) and NHS Health Research Authority (NRES) Committee South

Central–Oxford C (14/SC/1267).

Study Participants

Participants were between 18 and 45 years of age, had a singleton pregnancy, recruited from

antenatal diabetes clinics in Leeds Teaching Hospitals Trust and were diagnosed with GDM

according to National Institute for Health and Care Excellence (NICE) guideline criteria — i.e.,

fasting glucose ≥5.6 mmol/L (≤100.8 mg/dL) and/or 2-h glucose ≥7.8 mmol/L (≥140.4 mg/dL)

after a 75-g oral glucose tolerance test at ~26 weeks of gestation (3). As per clinical guidelines,

all women were advised to aim for self-monitored blood glucose (SMBG) targets: fasting glucose

<5.3 mmol/L and 1-h post meal <7.8 mmol/L (2, 28). Women were treated with diet and lifestyle

modifications as first-line therapy and with metformin and/or insulin as second-line therapy.

NICE guidelines state that if blood glucose targets are not achieved with diet and lifestyle

changes within 1 to 2 weeks, metformin will be offered(3). All women with GDM attending the

antenatal diabetes clinic at Leeds Teaching Hospital Trust were invited to participate. Exclusion

criteria included having a physical or psychological disease likely to interfere with the conduct of

the study, and not speaking English.

Continuous glucose monitoring (CGM)

The CGM device used was iPro2 (Medtronic). The CGM data was calibrated by simultaneous

SMBG using approved and standardized blood glucose meters and test strips (Contour XT;

Bayer) (26). Data was anonymised using a unique identification number for each participant and

was downloaded via CareLink (Medtronic) for analysis. The device measures glucose levels

every 5 minutes over a 24-hour period, providing 288 measures every day for 7 days. To analyse

mean glycemic control over a 24-hr period, the individual timepoint measurements were

averaged across 7 days. This provided 288 average measures of glucose over a 24-hr period.

To analyse key time points across the 24-hr day, the CGM glucose data was analysed by dividing

the data into four equal periods of six hours (e.g., morning 06:00-11:55, afternoon 12:00-17:55,

evening 18:00-23.55, and overnight 00:00-05.55). These windows were chosen so that the

morning, afternoon, and evening time periods include pre- and post-prandial glucose levels, and

the overnight time-period monitors a sleep cycle and a sustained fasted state. To evaluate

dysglycemia, our primary outcome of interest was coefficient of variation (CV). However,

additional indices were examined for the full 24hr hours and for each period, including: mean

glucose levels, standard deviation (SD), and the percentage of time spent within the pregnancy

glucose target range (TIR; 3.5–7.8 mmol/L [70.2– 140.4 mg/dL]), time spent above (TAR; >7.8

mmol/L [≥140.4 mg/dL]) and below (TBR; <3.5 mmol/L [≤70.2 mg/dL]) target range(27).

Nutritional data

In an exploratory analysis, complete nutritional information was available in a subgroup of 34 of

the 128 women with CGM data. Average daily dietary intake was collected using an online food

diary (myfood24)(29). Participants were instructed to complete the online record for 5 days.

Dietary intake was recorded as mean total grams or kilocalories per day. After removal of 1

participant with an implausible total kilocalorie intake <500 kcal/day (30), the nutrient residual

model was used to perform tests for linear association between individual macronutrients and

glycemic measures in 33 participants (31), after adjustment for maternal age, ethnicity, parity,

maternal BMI, and weeks of gestation (32, 33). Briefly, the nutrient residual model reduces

confounding by using the residuals of total energy intake, which represent the difference between

each individual's actual intake and the intake predicted by their total energy intake, thereby

removing the variation caused by total energy intake rather than absolute intake (31). Total

kilocalorie intake per day for each participant was standardised to the average energy intake per

day within our study (1500 kcal/day). To assess the association of macronutrients and glycemic

control, we constructed multiple variable regression models for each CGM metric (e.g., mean

glucose, SD, CV, AUC, iAUC, TIR, TAR or TBR). Each model CGM model included all

macronutrients— i.e., total carbohydrate intake (kcal) + total fat intake (kcal) + total energy

intake (kcal) — and covariates (maternal age, ethnicity, parity, maternal BMI, and weeks of

gestation). This model permits the assessment of substituting carbohydrates, fats, or proteins

(reflected by total energy intake) with an isocaloric equivalent quantity of the other

macronutrients. Specifically, these models examine the association of each macronutrient

independently with CGM metrics, when all other variables (i.e., other macronutrients, energy,

and covariates) are held constant. With three macronutrient sources of energy, when

'carbohydrates' and 'fats' are held constant, the increase in the 'calorie' variable represents an

increase in 'protein' (31).

Statistical analysis

Friedman's test and pairwise Wilcoxon signed rank test were used because of visually apparent

asymmetric data, with Bonferroni corrections applied for multiple comparisons between periods

of the day. Recent evidence suggests a difference in effect size of 0.924 (Cohen's d) on mean

glucose between diet and diet+metformin; therefore, at 80% power we required ≥ 21 participants

between comparison groups (34). To assess the association between dietary macronutrients and

glycaemic control, multiple variable linear regression analyses were performed and adjusted for

maternal age, ethnicity, parity, maternal BMI, and gestational week. The Cook's Distance was

used for influential outlier assessment. Statistical significance was set at $p<0.05$. All statistical

analyses were conducted in RStudio (version 4.0.3), and all figures were created in GraphPad

Prism 9.

Results

Over a 24-hour period, glucose measures were collected every 5 minutes, yielding a total of 288

glucose measurements per individual and a total of 36,864 glucose measurements for 128

women. In total, 34 women were excluded, due to incomplete participant data and <30% missing

CGM data across the 7 days. The majority of participants self-identified as white European (61%)

and managed their dysglycemia with diet alone (n=58), diet+metformin (n=51), diet+insulin

(n=2), or diet+metformin+insulin (n=17). Due to small numbers and inadequate power of insulin

and metformin+insulin treatment groups (i.e., <21 participants), analysis on treatment effect was

limited to diet and diet+metformin groups. The average age and BMI of participants was 33 years

and 30.6 kg/m^2. Approximately 30% of women, 34 out of 128 with available CGM data, used

myfood24 to record their dietary intake. Participant characteristics are summarised in **Table 1**.

CGM analysis

An effect of "time of day" was identified for the majority of CGM metrics — including, mean

glucose, SD, CV, AUC, iAUC, and TAR (**Figure 1 and Table 2**). Therefore, pairwise analyses

were performed on all CGM metrics. For CV and SD, measures were relatively stable during the

day but lowered 'overnight' (Figure 1). Conversely, glucose and total AUC increased steadily

from morning to evening and dropped overnight (mean glucose and AUC; all time comparisons

P>0.001). When focussing on measures of glycemic variability, SD and CV of glucose were

greatest in the morning and steadily decreased towards the lowest levels overnight (SD;

0.49mmol/L vs 0.30mmol/L and CV; 8.41% vs 4.99%, P<0.001). iAUC fluctuated over the 24-

hour period, with the highest levels recorded in the morning and evening (1244.5 vs 1311.6

mmol/L.min^{-1}, P=0.87), reductions in the afternoon (1106.0 mmol/L.min^{-1}, P<0.001) and

recording the lowest levels overnight (604.9 mmol/L.min^{-1}, P<0.001). The Friedman test reported

no significant differences when glucose levels were within (TIR), or below (TBR) a specific

range, no differences were confirmed between times-of-day either (Figure 1 and Table 2).

However, TAR significantly differs across the day and was highest during the evening (TAR

evening; 4.41%, P=0.018).

Exploratory Analysis

Treatment Data. Our exploratory post-hoc analysis of treatment included 109 women (n=58 in

diet subgroup and n=51 in diet+metformin). A significant association of treatment on mean

glucose and AUC was found ($F_{(3,1)}$=27.3, P<0.001 and $F_{(3,1)}$=28.9, p<0.001, respectively),

both mean glucose (5.65 vs 5.97mmol/L) and total AUC (8115.1 vs 8586.1 mmol/L.min^{-1}) was

higher in metformin subgroup. No interaction between time-of-day and treatment on CGM metric

was found.

Nutrient Data. Our exploratory analysis of nutritional data included 34 women (**Table 3**). Of the

8 CGM metrics assessed, mean glucose and AUC showed significant associations with dietary

mediators. To clarify, these models examine the association of each macronutrient with glycemic

metrics, when the other macronutrients are held at a constant level — e.g., carbohydrates when

intake of dietary fat and protein are held constant. With only three macronutrient sources of

energy (i.e., carbohydrates, fats, and protein), when 'carbohydrates' and 'fats' are held constant,

any increase in the 'calorie' variable represents an increase in 'protein' (31). After adjusting for

known confounders (i.e., maternal age, BMI, gestational age at CGM measurement, parity,

ethnicity, and treatment), an increase (+1 SD) of fats or carbohydrates associated with higher

mean 24-hr glucose and AUC glucose (**Table 4**), while dietary protein (+1SD) associated with

reduced mean 24-hr glucose (-0.91mmol/L; P=0.02) and AUC glucose (-1296 mmol/L.min^{-1};

P=0.021).

Discussion

In an observational cohort of 162 women with GDM, this study demonstrated that (i) CGM offers different methods of assessing glycemic health; (ii) measures of dysglycemia vary considerably over a 24-hour period; and (iii) distinct periods of day are prone to lower or higher levels of absolute glucose as well as glucose variability. Depending on the CGM metric used, 'morning' and 'overnight' showed to be times of greatest dysglycemia. More specifically, glucose levels were most variable during the day (morning to evening) but were stable in a healthy range (≈95% of the time), while 'overnight' showed extended periods of lower glucose levels with relatively less glucose variability. Additionally, exploratory analysis of the association between treatment type (diet vs diet+metformin), time-of-day and maternal glycemic control showed no significant interaction between treatment type and time-of-day on maternal glycemia over a mean 24h period. However, individuals assigned to diet with metformin appeared to have higher levels of dysglycemia, as reflected by elevated mean glucose and total AUC.

Current measures of dysglycemia often use fasting or mean glucose levels to evaluate glycemic control. In our analysis, we report the mean morning, afternoon, and evening glucose levels to be significantly higher compared to mean glucose levels overnight. This agrees with existing understanding of overnight glycemic control, with glucose levels typically falling overnight(35). However, recent work has speculated that glucose excursions quantify a health risk that is independent of mean glucose levels (36, 37). The proposed standard metric for glycemic variability is the CV of glucose (27, 37), which quantifies the magnitude of glycemic variability standardised to mean glucose levels. Despite seeing no difference in mean glucose levels between, afternoon, and evening, our study shows that CV steadily declines during the day reaching lowest values 'overnight' and reports that morning CV was significantly higher compared to other times-of-day. This agrees with trends observed in non-diabetic men and women (n=60) that reported significantly higher Daytime CV (06:00-21:59) compared to Overnight CV (22:00-05:59) (38) but disagrees with evidence from adolescent boys and girls (n=107; 13.1 ±2.6 years) that suggests CV increases from early morning (06:00) and peaks from midday to late-night (12:00-23:00) (39). However, the significance in temporal CV patterns was not formally assessed for adolescents, so its importance is uncertain. Recent work suggests that diabetes CV is involved with offspring growth in the 2nd trimester in women with type-1 diabetes

(40, 41), and may be an indicator of risk of future health complications associated with T2DM

(including cardiovascular disease, coronary events, non-cardiovascular mortality, and total

mortality) (4). Therefore, morning control of glucose variability (measured by SD and CV) may

be a key point of interest for managing maternal and offspring health. Increased morning CV in

this study's group of women might also be the result of a lack in regular routine, these women

may need to get their other children ready for school and/or get ready for work and may not have

time for breakfast.

Our exploratory post-hoc analysis of treatment effect demonstrated a significant relationship

between treatment group and 2 of the 8 CGM metrics showing persistent higher mean glucose

levels and total AUC in women treated with diet+metformin. Despite the lack of a significant

relationship between metformin treatment group and other CGM metrics, it is important to note

that blood glucose levels vary significantly day by day and glycemic control and variability

depend on a variety of different exogenous and endogenous determinants such as, elevated

insulin resistance, elevated hepatic glucose production, increased production of antagonistic

hormones to insulin, sedentary lifestyle, unhealthy dietary habits and age related metabolic

deterioration (42). Although metformin is the most commonly prescribed antihyperglycemic

medication for diabetes in the U.K., its effectiveness in glycemic control is only now being

documented. Noteworthy, metformin is only prescribed when women are failing to achieve

glucose targets with diet alone; therefore, glucose levels in this group are higher. Estimates from

recent trials suggest that at higher doses metformin can reduce HbA1c by 1–2% (11– 22

mmol/mol)(43), this is promising as it has been reported that a 1 % reduction in HbA1c in

women with GDM is associated with improved maternal and offspring outcomes (44).

Furthermore, a recent study by Bashir et al (20) found that women with GDM on pharmaceutical

treatment were diagnosed earlier than women on dietary treatment, and it is likely that early

treatment intensification with diet and metformin has led to reduced foetal glucose levels, foetal

hyperinsulinemia and macrosomia.

In our exploratory analysis, a subgroup of 34 participants recorded their dietary intake for 3 days

using myfood24 (29). According to the recommended daily intakes (RDI) set by the Diabetes

Care Programmes (45), carbohydrate and protein intake are both low and the fat intake is above

recommendations. Of the 8 CGM metrics assessed, mean glucose and AUC showed significant

associations with dietary mediators. Our exploratory analysis shows an increase in AUC and

glucose levels associated with carbohydrate and fat intake. Various dietary carbohydrates – e.g.

glucose, sucrose, cooked starches found in pastas and white bread) are readily digested and

absorbed in the small intestines, this contributes to a rapid increase in blood glucose (46). Other

studies have established that maternal glucose responses can be considerably influenced by the

total amount of carbohydrates consumed (46). Increased dietary fat intake (high in saturated fat)

has been associated with increased PPG levels and circulating fatty acids (47). Chronic increased

level of circulating fatty acids have been linked to increased insulin resistance and inflammation,

which are associated with risk of preeclampsia and preterm delivery (47, 48). Additionally,

previous studies have demonstrated that elevated PPGRs contribute to an increased glucose

transport to the foetus correlating with infant size and/or adiposity (46). Furthermore, our results

showed that increasing protein intake by 1 standard deviation (while holding dietary

carbohydrates and fats quantities constant) is associated with lower mean glucose and total AUC.

While current positions and recommendations of major health bodies [National Health Services

(UK), Canadian Diabetes Association, the American Diabetes Association, and the European

Association for the Study of Diabetes] focus on replacing low-quality processed (high glycemic-

index) carbohydrates with high-quality (low glycemic index) carbohydrates for diabetic patients,

our analysis positions protein as an additional dietary pathway to manage gestational

dysglycemia. The influence of protein on glycemia is likely to be explained by its more

efficacious effect stimulating a rise in glucagon levels than glucose is in suppressing it – i.e.

based on weight, protein is 10 times more efficacious than glucose in affecting the glucagon

response in normal individuals (18). A previous study has concluded that substituting some of the

fruit content with slowly digestible starch sources (e.g. legumes and al dente pasta, etc.), and

increasing the protein content may result in a diet that is more acceptable for management of

T2DM (49). Although this study was not designed to investigate interactions between

carbohydrates quality consumed and time of day, future studies may be appropriately designed to

investigate such an interaction and report on the importance of timing high nutritional-quality

meals to manage dysglycemia.

This study has offered insight into temporal changes of dysglycemia and demonstrated the value

of commonly reported CGM metrics, however, there are limitations to the study. First, although

the study population was ethnically diverse (≈40% non-European ancestry), all women were

diagnosed with GDM according to U.K. NICE criteria (3); therefore, our study population may

not be representative of women diagnosed for GDM by alternative criteria (e.g., IADPSG –

International Association of Diabetes and Pregnancy Study Group) (50, 51). Second, the CGM

data were obtained at one time-period of gestation, which may not be representative of glycemia

at other times during the pregnancy. Third, due to unequal number of total measurements

between days and participants, we chose to average the 7-days data (that was available for

participants) into a 24-hr period to analyse. While this prevented us from assessing a glucose

shifts over multiple days or comparing weekdays and weekends, it allowed us to identify

timepoints in a 24-hour period where glucose excursions were common. Finally, dietary logs

were available only for a subgroup of participants and their mealtimes were not recorded;

nonetheless, our analyses suggest future investigations of the role of dietary protein and

carbohydrate quality on dysglycemia are warranted.

In summary, these results confirm that CGM is a rich source of information that could detect and

quantify periods of dysglycemia. Additionally, we demonstrate that each of the metrics available

to characterise CGM data, offers unique information to characterise an individual glucose profile

and its variability. Therefore, demonstrating the complexity of maternal dysglycemia, which is

not easily summarised by a single glycemic metric. Moreover, individuals assigned to diet with

metformin appeared to have the greatest difficulty managing glycemia, suggesting the need for

more directed care and follow-up may benefit this group of individuals. Finally, our exploratory

analysis suggests that increased protein intake may assist with dysglycemia management, and that

consideration of both protein and carbohydrate quality may provide optimal support for managing

dysglycemia.

Acknowledgements: The authors thank all the participants of the original study. The authors
would also acknowledge the invaluable support from the diabetes antenatal care teams involved
during original data collection.

Author contributions: EMS designed the original study protocol. CFD, EMS and MAZ
contributed to design of secondary analysis plan. EMS provided the CGM in GDM dataset. JEC
provided the dietary data in the dataset. CFD and MAZ prepared the data for analysis. CFD,
MAZ, JEC, EMS, and MJH contributed to the data analysis and statistical analysis. CFD and
MAZ have primary responsibility for the final content. CFD wrote the first draft of the
manuscript. EMS, MDC, JEC, and MJH provided critical feedback. CFD, MAZ, EMS, MDC,
JEC, and MJH read and approved the final manuscript. CFD and MAZ is the guarantor of this
work and, as such, takes responsibility for the integrity of the data and the accuracy of the data
analysis.

Data sharing plan: Data described in the manuscript and analytic code will be made available
upon request pending application and approval.

References

1. Powe CE, Huston Presley LP, Locascio JJ, Catalano PM. Augmented insulin secretory response in early pregnancy. Diabetologia 2019;62(8):1445-52. PubMed PMID: 31177313; PubMed Central PMCID: PMCPMC6786902.

2. Law GR, Alnaji A, Alrefaii L, Endersby D, Cartland SJ, Gilbey SG, Jennings PE, Murphy HR, Scott EM. Suboptimal nocturnal glucose control is associated with large for gestational age in treated gestational diabetes mellitus. Diabetes Care 2019;42(5):810-5.

3. Webber J, Charlton M, Johns N. Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). British Journal of Diabetes 2015;15(3):107-11.

4. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. J Diabetes Res 2019;2019: Article ID 5320156. PubMed PMID: 31828161; PubMed Central PMCID: PMCPMC6885766.

5. Salzer L, Tenenbaum-Gavish K, Hod M. Metabolic disorder of pregnancy (understanding pathophysiology of diabetes and preeclampsia). Best Pract Res Clin Obstet Gynaecol 2015;29(3):328-38. PubMed PMID: 25481558.

6. Filardi T, Panimolle F, Crescioli C, Lenzi A, Morano S. Gestational diabetes mellitus: The impact of carbohydrate quality in diet. Nutrients 2019;11(7):1549.

7. Moncrieff G. Gestational diabetes. British Journal of Midwifery 2018;26(8):506-13.

8. Hunt KF, Whitelaw BC, Gayle C. Gestational diabetes. Obstetrics, Gynaecology & Reproductive Medicine 2014;24(8):238-44.

9. Panyakat WS, Phatihattakorn C, Sriwijitkamol A, Sunsaneevithayakul P, Phaophan A, Phichitkanka A. Correlation between third trimester glycemic variability in non-insulin-dependent gestational diabetes mellitus and adverse pregnancy and fetal outcomes. Journal of diabetes science and technology 2018;12(3):622-9.

10. Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. The Lancet 2002;359(9318):1690-2.

11. Schaefer-Graf U, Napoli A, Nolan CJ. Diabetes in pregnancy: a new decade of challenges ahead. Diabetologia 2018;61(5):1012-21.

12. Feig DS, Bonomo MA. Technology and Diabetes in Pregnancy. Edtion ed. Gestational Diabetes: Karger Publishers, 2020:88-108.

13. McCance DR. Diabetes in pregnancy. Best practice & research Clinical obstetrics & gynaecology 2015;29(5):685-99.

14. Xu J, Ye S. Influence of low-glycemic index diet for gestational diabetes: A meta-analysis of randomized controlled trials. The Journal of Maternal-Fetal & Neonatal Medicine 2020;33(4):687-92.

15. Vega-López S, Ausman LM, Griffith JL, Lichtenstein AH. Interindividual variability and intra-individual reproducibility of glycemic index values for commercial white bread. Diabetes care 2007;30(6):1412-7.

16. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M. Personalized nutrition by prediction of glycemic responses. Cell 2015;163(5):1079-94.

17. Matthan NR, Ausman LM, Meng H, Tighiouart H, Lichtenstein AH. Estimating the reliability of glycemic index values and potential sources of methodological and biological variability. The American journal of clinical nutrition 2016;104(4):1004-13.

18. Meng H, Matthan NR, Ausman LM, Lichtenstein AH. Effect of macronutrients and fiber on postprandial glycemic responses and meal glycemic index and glycemic load value determinations. The American journal of clinical nutrition 2017;105(4):842-53.

19. Meng H, Matthan NR, Ausman LM, Lichtenstein AH. Effect of prior meal macronutrient composition on postprandial glycemic responses and glycemic index and glycemic load value determinations. The American journal of clinical nutrition 2017;106(5):1246-56.

20. Bashir M, Aboulfotouh M, Dabbous Z, Mokhtar M, Siddique M, Wahba R, Ibrahim A, Brich SA-H, Konje JC, Abou-Samra A-B. Metformin-treated-GDM has lower risk of macrosomia compared to diet-treated GDM-a retrospective cohort study. The Journal of Maternal-Fetal & Neonatal Medicine 2020;33(14):2366-71.

21. Zhang X, Xu D, Xu P, Yang S, Zhang Q, Wu Y, Yuan F. Metformin improves glycemic variability in adults with type 1 diabetes mellitus: an open-label randomized control trial. Endocrine Connections 2021;10(9):1045-54.

22. Joseph CMC. Symptomatic Hypoglycemia During Treatment with a Therapeutic Dose of Metformin. [Internet]. The American Journal of Case Reports. 2021 Jun [cited 2022 Sep 13];22:e931311-1. Pubmed Central PMCID: PMC8183305; Pubmed PMID: 34075013.

23. Simeonova-Krstevska S, Bogoev M, Bogoeva K, Zisovska E, Samardziski I, Velkoska-Nakova V, Livrinova V, Todorovska I, Sima A, Blazevska-Siljanoska V. Maternal and neonatal outcomes in pregnant women with gestational diabetes mellitus treated with diet, metformin or insulin. Open access Macedonian journal of medical sciences 2018;6(5):803.

24. Scott EM, Feig DS, Murphy HR, Law GR. Continuous glucose monitoring in pregnancy: importance of analyzing temporal profiles to understand clinical outcomes. Diabetes Care 2020;43(6):1178-84.

25. Tan E, Scott EM. Circadian rhythms, insulin action, and glucose homeostasis. Current Opinion in Clinical Nutrition & Metabolic Care 2014;17(4):343-8.

26. Law GR, Ellison GTH, Secher AL, Damm P, Mathiesen ER, Temple R, Murphy HR, Scott EM. Analysis of continuous glucose monitoring in pregnant women with diabetes: distinct temporal patterns of glucose associated with large-for-gestational-age infants. Diabetes Care 2015;38(7):1319-25.

27. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA. International consensus on use of continuous glucose monitoring. Diabetes care 2017;40(12):1631-40.

28. Meek CL, Tundidor D, Feig DS, Yamamoto JM, Scott EM, Ma DD, Halperin JA, Murphy HR, Corcoy R. Novel biochemical markers of glycemia to predict pregnancy outcomes in women with type 1 diabetes. Diabetes Care 2021;44(3):681-9.

29. Gianfrancesco C, Darwin Z, McGowan L, Smith DM, Haddrill R, Carter M, Scott EM, Alwan NA, Morris MA, Albar SA. Exploring the feasibility of use of an online dietary assessment tool (myfood24) in women with gestational diabetes. Nutrients 2018;10(9):1147.

30. NutriGen Alliance, de Souza RJ, Zulyniak MA, Desai D, Shaikh MR, Campbell NC, Lefebvre DL, Gupta M, Wilson J, Wahi G. Harmonization of food-frequency questionnaires and dietary pattern analysis in 4 ethnically diverse birth cohorts. The Journal of nutrition 2016;146(11):2343-50.

31. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. The American journal of clinical nutrition 1997;65(4):1220S-8S.

32.   Zhang C, Liu S, Solomon CG, Hu FB. Dietary fiber intake, dietary glycemic load, and the risk for gestational diabetes mellitus. Diabetes care 2006;29(10):2223-30.

33.   Van Leeuwen M, Opmeer BC, Zweers EJK, Van Ballegooie E, Ter Brugge HG, De Valk HW, Visser GHA, Mol BWJ. Estimating the risk of gestational diabetes mellitus: a clinical prediction model based on patient characteristics and medical history. BJOG: An International Journal of Obstetrics & Gynaecology 2010;117(1):69-75.

34.   Afandi BO, Hassanein MM, Majd LM, Nagelkerke NJD. Impact of Ramadan fasting on glucose levels in women with gestational diabetes mellitus treated with diet alone or diet plus metformin: a continuous glucose monitoring study. BMJ Open Diabetes Research and Care 2017;5(1):e000470.

35.   Zaharieva DP, Teng JH, Ong ML, Lee MH, Paldus B, Jackson L, Houlihan C, Shub A, Tipnis S, Cohen O. Continuous Glucose Monitoring Versus Self-Monitoring of blood glucose to assess glycemia in gestational diabetes. Diabetes Technology & Therapeutics 2020;22(11):822-7.

36.   Zaccardi F, Khunti K. Glucose dysregulation phenotypes—time to improve outcomes. Nature Reviews Endocrinology 2018;14(11):632-3.

37.   Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? Journal of diabetes science and technology 2008;2(6):1094-100.

38.   Barua S, Sabharwal A, Glantz N, Conneely C, Larez A, Bevier W, Kerr D. Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoring. EClinicalMedicine 2021;35:100853.

39.   Zhu J, Volkening LK, Laffel LM. Distinct patterns of daily glucose variability by pubertal status in youth with type 1 diabetes. Diabetes Care 2020;43(1):22-8.

40.   Scott ES, Januszewski AS, O'Connell R, Fulcher G, Scott R, Kesaniemi A, Wu L, Colagiuri S, Keech A, Jenkins AJ. Long-term glycemic variability and vascular complications in type 2 diabetes: post hoc analysis of the FIELD study. The Journal of Clinical Endocrinology & Metabolism 2020;105(10):e3638-e49.

41.   Kristensen K, Ögge LE, Sengpiel V, Kjölhede K, Dotevall A, Elfvin A, Knop FK, Wiberg N, Katsarou A, Shaat N. Continuous glucose monitoring in pregnant women with type 1

diabetes: an observational cohort study of 186 pregnancies. Diabetologia 2019;62(7):1143-53.

42. Martínez-Abundis E, González-Heredia T, Hernández-Corona DM, González-Ortiz M. Effect of metformin on glycemic variability and glycemic control in patients with prediabetes. Biomedical Research 2018;29(21):3774-8.

43. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes care 2012;35(2):446-54.

44. Kiefer MK, Finneran MM, Ware CA, Fareed N, Joseph J, Thung SF, Costantine MM, Landon MB, Gabbe SG, Venkatesh KK. Association of change in haemoglobin A1c with adverse perinatal outcomes in women with pregestational diabetes. Diabetic Medicine 2022;39(7):e14822.

45. Kapur K, Kapur A, Hod M. Nutrition management of gestational diabetes mellitus. Annals of Nutrition and Metabolism 2020;76(3):17-29.

46. Mustad VA, Huynh DTT, López-Pedrosa JM, Campoy C, Rueda R. The role of dietary carbohydrates in gestational diabetes. Nutrients 2020;12(2):385.

47. Lichtenstein AH, Schwab US. Relationship of dietary fat to glucose metabolism. Atherosclerosis 2000;150(2):227-43.

48. Chen X, Scholl TO, Leskiw M, Savaille J, Stein TP. Differences in maternal circulating fatty acid composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. Diabetes care 2010;33(9):2049-54.

49. Gannon MC, Nuttall FQ, Westphal SA, Fang S, Ercan-Fang N. Acute metabolic response to high-carbohydrate, high-starch meals compared with moderate-carbohydrate, low-starch meals in subjects with type 2 diabetes. Diabetes Care 1998;21(10):1619-26.

50. Coustan DR. Gestational diabetes mellitus. Clinical chemistry 2013;59(9):1310-21.

51. Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Ramezani Tehrani F. The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. Diabetology & metabolic syndrome 2019;11(1):1-18.

Table 1. Participant characteristics

Characteristics	Total group (n=128)	Nutrition measure subgroup (n=34)	Diet subgroup (n=58)	Diet+metformin subgroup (n=51)
Age (yrs)	33.0 ± 4.5	32.2 ± 5.0	32.8 ± 4.8	33.4 ± 5.1
BMI at start of pregnancy(kg/m^2)	30.5 ± 6.1	29.7 ± 5.9	28.9 ± 5.7	31.1 ± 6.4
Gestational week	31.1 ± 1.2	31.5 ± 1.2	31.1 ± 1.3	31.1 ± 1.1
Parity	1.0 ± 1.1	1.0 ± 0.6	1 ± 1.3	1 ± 0.9
Treatment				
Diet	58 (53%)	18 (53%)	58 (100%)	0
Diet+metformin	51 (47%)	16 (47%)	0	51 (100%)
Ethnicity				
White European	78 (61%)	25 (74%)	34 (59%)	27 (53%)
Ethnic minority (Black or Asian)	50 (39%)	9 (26%)	24 (41%)	24 (47%)

Table 2. Summary of measures of continuous glucose monitoring CGM over a 24-hour period.

	Daily Average	Morning (6:00-11:55)	Afternoon (12:00-17:55)	Evening (18:00-23:55)	Overnight (24:00-5:55)
			Glucose (mmol/L)		
Mean±SD	5.86±0.64	5.76±0.60^a	6.02±0.72^b	6.17±0.71^c	5.51±0.64^d
95% CI	[5.75 , 5.97]	[5.66 , 5.87]	[5.89 , 6.14]	[6.04 , 6.29]	[5.38 , 5.64]
			Standard deviation of Glucose (mmol/L)		
Mean±SD	0.57±0.21	0.49±0.45^a	0.43±0.22^b	0.41±0.20^{b,c}	0.30±0.22^d
95% CI	[0.54 , 0.61]	[0.45, 0.53]	[0.40 , 0.47]	[0.38 , 0.45]	[0.26 , 0.33]
			Coefficient of variation of Glucose (%)		
Mean±SD	9.76±3.36	8.41±4.17^a	7.35±3.32^b	7.08±3.22^{b,c}	4.99±3.38^d
95% CI	[9.18 , 10.35]	[7.69 , 9.14]	[6.78 , 7.93]	[6.52 , 7.64]	[4.40 , 5.58]
			Area Under the Curve of Glucose (AUC; mmol/L.min^{-1})		
Mean±SD	8433.8±913.9	2073.7±216.8^a	2160.5±260.8^b	2218.6±255.8^c	1980.9±276.9^d
95% CI	[8275.4, 8592.1]	[2036.2, 2111.3]	[2115.4, 2205.7]	[2174.3, 2262.9]	[1932.9, 2028.8]
			Incremental Area Under the Curve of Glucose (iAUC; mmol/L.min^{-1})		
Mean±SD	3606.4±1034.5	1244.5±354.3^a	1106.0±318.1^b	1311.6±349.0^{a,c}	604.9±393.1^d
95% CI	[3427.2, 3785.6]	[1183.1, 1305.9]	[1050.8, 1161.1]	[1251.1, 1372.0]	[536.8 , 673.0]
			Time in Range Metrics		
TIR (% of day)	96.91 ±9.35	98.46±5.70^a	96.03±14.55^a	95.59±15.17^a	97.57±11.92^a
TAR (% of day)	2.90 ±9.16	1.5±5.69^a	3.97±14.55^a	4.41±15.17^a	1.71±8.88^a
TBR (% of day)	0.19 ±2.15	0.04±0.49^a	0.0±0.0^a	0.0±0.0^a	0.72±8.10^a

All time metrics are mean measures across 7-days: TIR, time with glucose level measured within 3.5-7.8 mmol/L; TAR, time with glucose level measured above 7.8mmol/L; TBR, time with glucose level measured below 3.5mmol/L. Significant differences between times of day (P<0.05) for individual metrics are denoted by different superscripts. The figures show each CGM metric and time-of-day, for visual aid.

Table 3. Nutritional intake: Average values of nutrients intake reported by random subsample of 39 participants that maintained dietary records.

	Daily intake (kcal/day) (% total kcal/day)	**Daily intake** (gram/day)
Protein	246±92 (16%)	61±26
Fats	577±290 (38%)	64±33
Carbohydrates	716±311 (47%)	176±74
Non-sugar	474±208	117±50
Sugar	242±179	59±43
Total intake	1513±517	N/A

Data reported as mean intake ± standard deviation (SD) per day of each nutrient and total energy intake. Mean proportion of nutrients of total caloric intake reported in parentheses.

Table 4. Multivariable regression of dietary mediators (carbohydrates, fats, and protein) and glycemia stratified by outcome metric of 34 participants that maintained dietary records and had

	Mean glucose (mmol/L)		AUC (mmol/L.min^{-1})	
Variables	**β (95% CI)**	**P-value**	**β (95% CI)**	**P-value**
Age	*-0.015 (-0.05, 0.02)*	*0.38*	*-22.1 (-70.2, 25.9)*	*0.38*
Maternal BMI	*0.022 (-0.005, 0.05)*	*0.12*	*31.8 (-7.1, 70.7)*	*0.12*
Gestational week	*0.009 (-0.12, 0.14)*	*0.89*	*12.5 (-173.3, 198.3)*	*0.90*
Parity	*0.093 (-0.24, 0.28)*	*0.49*	*132.5 (-240.4, 505.3)*	*0.50*
Ethnicity	*0.22 (-0.36, 0.4)*	*0.93*	*23.2 (-526.2, 572.6)*	*0.93*
Treatment type	*0.17 (-0.08, 0.52)*	*0.17*	*315.5 (-121.5, 752.5)*	*0.17*
Adjusted carbohydrates	0.63 (0.13, 1.1)	**0.021**	887.9 (173.6, 1602.2)	**0.023**
Adjusted fats	0.49 (0.04, 0.93)	**0.043**	694.7 (48.5, 1340.8)	**0.046**
Adjusted protein	-0.91 (-0.2, -1.6)	**0.02**	-1296.0 (-265.0, -2327.0)	**0.021**

CGM metrics available.

Mean glucose r^2 =0.32, AUC r^2 =0.18. Treatment was coded as follows: 0=diet, 1=diet+metformin. Parity was reported as having 0, 1, 2, 3, 4, 5 or 6 children. Ethnicity was coded as: 0=White and 1=Ethnic minority (e.g., Asian, Black African). CI = confidence interval. Significant associations (P<0.05) in bold.

LEGENDS FOR FIGURES

Figure 1. Mean measures of continuous glucose monitoring CGM across distinct periods of a for 128 women with GDM.